Original research

Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)

Hayley Holt, Mohammad Talaei, Matthew Greenig, Dominik Zenner, Jane Symons, Clare Relton, Katherine S Young, Molly R Davies, Katherine N Thompson, Jed Ashman, Sultan Saeed Rajpoot, Ahmed Ali Kayyale, Sarah El Rifai, Philippa J Lloyd, David Jolliffe, Olivia Timmis, Sarah Finer, Stamatina Iliodromiti, Alec Miners, Nicholas S Hopkinson, Bodrul Alam, Graham Lloyd-Jones, Thomas Dietrich, Iain Chapple, Paul E Pfeffer, David McCoy, Gwyneth Davies, Ronan A Lyons, Christopher Griffiths, Frank Kee, Aziz Sheikh, Gerome Breen, Seif O Shaheen, Adrian R Martineau

ABSTRACT

Background Risk factors for severe COVID-19 include older age, male sex, obesity, black or Asian ethnicity and underlying medical conditions. Whether these factors also influence susceptibility to developing COVID-19 is uncertain.

Methods We undertook a prospective, population-based cohort study (COVIDENCE UK) from 1 May 2020 to 5 February 2021. Baseline information on potential risk factors was captured by an online questionnaire. Monthly follow-up questionnaires captured incident COVID-19. We used logistic regression models to estimate multivariable-adjusted ORs (aORs) for associations between potential risk factors and odds of COVID-19.

Results We recorded 446 incident cases of COVID-19 in 15,227 participants (2.9%). Increased odds of developing COVID-19 were independently associated with Asian/Asian British versus white ethnicity (aOR 2.28, 95% CI 1.33 to 3.91), household overcrowding (aOR per additional 0.5 people/bedroom 1.26, 1.11 to 1.43), any versus no visits to/from other households in previous week (aOR 1.31, 1.06 to 1.62), number of visits to indoor public places (aOR per extra visit per week 1.05, 1.02 to 1.09), frontline occupation excluding health/social care versus no frontline occupation (aOR 1.49, 1.12 to 1.98) and raised body mass index (BMI) (aOR 1.50 (1.19 to 1.89) for BMI 25.0–30.0 kg/m² and 1.39 (1.06 to 1.84) for BMI >30.0 kg/m² versus BMI <25.0 kg/m²). Atopic disease was independently associated with decreased odds (aOR 0.75, 0.59 to 0.97). No independent associations were seen for age, sex, other medical conditions, diet or micronutrient supplement use.

Conclusions After rigorous adjustment for factors influencing exposure to SARS-CoV-2, Asian/Asian British ethnicity and raised body mass index were associated with increased risk of developing COVID-19, while atopic disease was associated with decreased risk; no associations were seen for age, sex or other underlying medical conditions.

Key messages

What is the key question?
⇒ How do demographic, socioeconomic, lifestyle, dietary, pharmacological and comorbidity factors relate to the risk of developing COVID-19 in the general adult population of the UK?

What is the bottom line?
⇒ After rigorous adjustment for factors influencing exposure to SARS-CoV-2, Asian/Asian British ethnicity and raised body mass index were associated with increased risk of developing COVID-19, while atopic disease was associated with decreased risk; no associations were seen for age, sex or other underlying medical conditions.

Why read on?
⇒ This large, population-based prospective study shows that there is limited overlap between risk factors for developing COVID-19 versus those for intensive care unit admission and death as reported in hospitalised cohorts.

INTRODUCTION

COVID-19 has taken a heavy toll on the health of populations globally.1–3 Risk factors for severe and fatal disease are well recognised, and include male sex, black or Asian ethnic origin, obesity, deprivation and a range of comorbidities including diabetes mellitus, cardiovascular disease, COPD and hypertension.4–6 Characterisation of risks for milder disease has been relatively neglected, but is important, both from a public health perspective (since it drives transmission to individuals at risk of severe disease), and from a biological perspective (since understanding susceptibility factors can provide insights into pathogenesis).

There is growing evidence from population-based studies to suggest that at least some risk factors for
developing COVID-19—irrespective of severity—may be distinct from those which predispose to disease at the most severe end of the spectrum. For example, population-based studies in both the USA and the UK have reported that risk of COVID-19 is higher in younger versus older adults, a finding supported by serology studies in the UK and Switzerland reporting higher prevalence of antibodies to SARS-CoV-2 in younger versus older adults. Again, in contrast to studies reporting that diabetes, heart disease and hypertension are risk factors for severe disease, the presence and extent of pre-existing health conditions has been reported to associate with decreased, rather than increased, risk of SARS-CoV-2 seropositivity in a population-based study conducted in the UK. These apparently paradoxical associations are potentially attributable to changes in behaviour in response to the pandemic, whereby people at greater risk of severe disease because of older age or presence of comorbidities may reduce social contact and visits to indoor public places in order to reduce their exposure to SARS-CoV-2. However, to our knowledge, studies to investigate whether behaviours influencing risk of such exposure might partly explain associations between older age, presence of comorbidities and lower risk of developing COVID-19 are lacking. Such studies could potentially shed light on other controversies relating to risk factors for developing COVID-19, such as the extent to which ethnic differences in disease susceptibility can be explained by behavioural, occupational and socioeconomic factors, and whether lifestyle, diet and use of micronutrient supplements may influence risk of developing COVID-19.

In order to address this knowledge gap, we established a new longitudinal study (COVIDENCE UK) at the start of the pandemic, with the specific aim of capturing detailed information on a very wide range of potential risk factors for COVID-19. Sufficient incident cases of test-confirmed COVID-19 have now accumulated to allow us to evaluate how a comprehensive panel of demographic, socioeconomic, lifestyle, dietary, pharmacological and comorbidity factors relate to the risk of developing COVID-19.

METHODS

Study design, setting and participants

COVIDENCE UK is a prospective longitudinal population-based observational study of coronavirus disease in the UK population (www.qmul.ac.uk/covidence). Inclusion criteria are age 16 years or more and residence in the UK at the point of enrolment; there are no exclusion criteria. Participants were invited via a national media campaign to complete an online baseline questionnaire to capture information on potential symptoms of COVID-19 experienced since 1 February 2020, results of any COVID-19 tests and details of a wide range of potential risk factors for COVID-19, as described below. Follow-up questionnaires were administered at monthly intervals to capture incident test-confirmed COVID-19 as well as potential symptoms of COVID-19. The study was launched on 1 May 2020, and this paper reports findings of analysis of data collected up to 5 February 2021.

Outcomes

The primary outcome was incidence of test-confirmed COVID-19, as defined by a self-reported positive result from PCR or lateral flow testing of eluate from a nose or throat swab for SARS-CoV-2. Those who were not tested were assumed to be test negative. The secondary outcome was incidence of symptom-defined probable COVID-19, with casehood defined using the algorithm described by Menni et al., based on age, sex and self-reported loss of smell/taste, significant/severe persistent cough, severe fatigue and skipped meals (see online supplemental appendix for further details). This outcome was included in order to address potential underascertainment of COVID-19 arising from use of test-confirmed COVID-19 as an outcome measure, which would not have captured episodes where testing was not done, potentially introducing collider bias. Test-confirmed COVID-19 and symptom-defined probable COVID-19 were analysed as separate outcomes (ie, they were not combined). In order to minimise the potential for reverse causality to explain associations observed, outcomes occurring within 30 days of enrolment were excluded. At enrolment, participants were asked to provide details of potential symptoms of COVID-19 experienced since 1 February 2020, and results of any PCR or lateral flow tests for SARS-CoV-2 performed on eluates from nose/throat swabs to date.

Independent variables

At enrolment, participants were asked to complete an online questionnaire capturing information about their sociodemographic characteristics, type of occupation, lifestyle, weight, height, long-standing medical conditions, medication use, vaccination status, diet and supplemental micronutrient intake (for baseline questionnaire, see online supplemental table 1). Monthly online follow-up questionnaires (online supplemental...
Table 1  Selected cohort characteristics

| Characteristics                      | Total | Test-confirmed COVID-19 |
|--------------------------------------|-------|-------------------------|
|                                      | No    | Yes                     |
| n (%)                                | 15227 (86.7) | 14781 (97.1) | 446 (2.9) |
| Age, n (%)                           | 16–29.99 years: 576 (3.8) | 550 (3.7) | 26 (5.8) |
|                                      | 30–39.99 years: 988 (6.5) | 941 (6.4) | 47 (10.5) |
|                                      | 40–49.99 years: 1787 (11.7) | 1693 (11.5) | 94 (21.1) |
|                                      | 50–59.99 years: 3361 (22.1) | 3226 (21.8) | 135 (30.3) |
|                                      | 60–69.99 years: 5105 (33.5) | 5008 (33.9) | 97 (21.7) |
|                                      | >70.00 years: 3410 (22.4) | 3363 (22.8) | 47 (10.5) |
| Sex, n (%)                           | Female: 10630 (69.8) | 10301 (69.7) | 329 (73.8) |
|                                      | Male: 4597 (30.2) | 4480 (30.3) | 117 (26.2) |
| Ethnicity, n (%)                     | White: 14449 (94.9) | 14046 (95.0) | 403 (90.4) |
|                                      | Mised/multiple/other ethnic groups: 401 (2.6) | 382 (2.6) | 19 (4.3) |
|                                      | South Asian: 281 (1.8) | 263 (1.8) | 18 (4.0) |
|                                      | Black/African/Caribbean/black British: 96 (0.6) | 90 (0.6) | 6 (1.3) |
| Country of residence, n (%)          | England: 13463 (88.4) | 13052 (88.3) | 411 (92.2) |
|                                      | Northern Ireland: 294 (1.9) | 281 (1.9) | 13 (2.9) |
|                                      | Scotland: 915 (6.0) | 910 (6.2) | 5 (1.1) |
|                                      | Wales: 555 (3.6) | 538 (3.6) | 17 (3.8) |
| Household income sufficient for basic needs, n (%) | Yes: 14209 (93.3) | 13793 (93.3) | 416 (93.3) |
|                                      | Mostly/sometimes/no: 1016 (6.7) | 986 (6.7) | 30 (6.7) |
| Housing, n (%)                       | Owns own home: 9326 (61.3) | 9137 (61.8) | 189 (42.4) |
|                                      | Mortgage: 3743 (24.6) | 3570 (24.2) | 173 (38.8) |
|                                      | Privately renting: 1069 (7.0) | 1029 (7.0) | 40 (9.0) |
|                                      | Renting from council: 477 (3.1) | 461 (3.1) | 16 (3.6) |
|                                      | Others: 610 (4.0) | 582 (3.9) | 28 (6.3) |
| Number of people per bedroom, n (%)  | ≤0.50: 5836 (38.6) | 5738 (39.1) | 98 (22.3) |
|                                      | >0.5–0.99: 4179 (27.6) | 4069 (27.7) | 110 (25.0) |
|                                      | 1.00–1.99: 4766 (31.5) | 4553 (31.0) | 213 (48.4) |
|                                      | ≥2.0: 333 (2.2) | 314 (2.1) | 19 (4.3) |
| Highest educational level attained, n (%) | Primary/secondary: 1649 (10.8) | 1598 (10.8) | 51 (11.4) |
|                                      | Higher/further (A levels): 2233 (14.7) | 2164 (14.7) | 69 (15.5) |
|                                      | College: 6720 (44.2) | 6523 (44.2) | 197 (44.2) |
|                                      | Postgraduate: 4610 (30.3) | 4481 (30.3) | 129 (28.9) |
| Occupational status, n (%)           | Employed: 5349 (35.1) | 5091 (34.4) | 258 (57.8) |
|                                      | Self-employed: 1369 (9.0) | 1330 (9.0) | 39 (8.7)

Table 1 Continued

| Characteristics                      | Total | Test-confirmed COVID-19 |
|--------------------------------------|-------|-------------------------|
|                                      | No    | Yes                     |
| Retired, n (%)                       | 6951 (45.6) | 6856 (46.4) | 95 (21.3) |
| Furloughed, n (%)                    | 365 (2.4) | 348 (2.4) | 17 (3.8) |
| Unemployed, n (%)                    | 267 (1.8) | 254 (1.7) | 13 (2.9) |
| Other, n (%)                         | 926 (6.1) | 902 (6.1) | 24 (5.4) |
| Frontline worker, n (%)              | No: 12474 (82.0) | 12198 (82.6) | 276 (61.9) |
|                                      | Other frontline worker: 1572 (10.3) | 1492 (10.1) | 80 (17.9) |
|                                      | Health or social care worker: 1167 (7.7) | 1077 (7.3) | 90 (20.2) |
| Body mass index, n (%)               | <25 kg/m²: 7431 (48.9) | 7254 (49.2) | 177 (39.8) |
|                                      | 25–30 kg/m²: 4829 (31.8) | 4661 (31.6) | 168 (37.8) |
|                                      | >30 kg/m²: 2929 (19.3) | 2829 (19.2) | 100 (22.5) |
| Self-reported general health, n (%)  | Excellent: 3071 (20.2) | 2982 (20.2) | 89 (20.0) |
|                                      | Very good: 6024 (39.6) | 5850 (39.6) | 174 (39.0) |
|                                      | Good: 4048 (26.6) | 3928 (26.6) | 120 (26.9) |
|                                      | Fair: 1633 (10.7) | 1581 (10.7) | 52 (11.7) |
|                                      | Poor: 449 (2.9) | 438 (3.0) | 11 (2.5) |
| Tobacco smoking history, n (%)       | Never smoker: 8529 (56.0) | 8282 (56.0) | 247 (55.4) |
|                                      | Ex-smoker: 5862 (38.5) | 5697 (38.5) | 165 (37.0) |
|                                      | Current smoker: 836 (5.5) | 802 (5.4) | 34 (7.6) |
| Alcohol consumption in week prior to questionnaire completion, n (%) | None: 4271 (28.1) | 4152 (28.1) | 119 (26.7) |
|                                      | 1–7 units: 5406 (35.5) | 5244 (35.5) | 162 (36.3) |
|                                      | 8–14 units: 2961 (19.4) | 2876 (19.5) | 85 (19.1) |
|                                      | 15–21 units: 1417 (9.3) | 1366 (9.2) | 51 (11.4) |
|                                      | 22–28 units: 657 (4.3) | 640 (4.3) | 17 (3.8) |
|                                      | ≥28 units: 529 (3.5) | 501 (3.4) | 12 (2.7) |
| COVID-19 vaccine during follow-up, n (%) | No: 14529 (85.7) | 12675 (85.8) | 365 (81.8) |
|                                      | Yes: 2416 (14.3) | 2106 (14.2) | 81 (18.2) |

Table 2 captured incident test-confirmed COVID-19 and potential symptoms of COVID-19.

Sample size and statistical methods

The sample size calculation and full details of statistical methods are presented in the online supplemental appendix. Participants who reported definite COVID-19 prior to enrolment, or who were classified as having had symptom-defined probable COVID-19 prior to enrolment on the basis of self-reported symptoms, were excluded from prospective analyses. Logistic regression models were used to estimate ORs and 95% CIs for potential determinants of COVID-19 risk, first in a crude model, then in minimally adjusted and fully adjusted models. Correction for multiple comparisons was not applied, on the grounds that we were testing a priori hypotheses for all risk factors investigated. We conducted sensitivity analysis for unmeasured
Table 2  Sociodemographic, occupational and lifestyle factors and risk of test-confirmed COVID-19: crude and minimally adjusted ORs

| Factor                                      | Total number | Crude OR (95% CI) | Minimally adjusted OR (95% CI)* |
|---------------------------------------------|--------------|-------------------|---------------------------------|
| **Age, years**                              |              |                   |                                 |
| 16–29.99                                    | 26 (4.5)     | 1.00              | 1.00                            |
| 30–39.99                                    | 47 (4.8)     | 1.06 (0.65 to 1.73)| 1.08 (0.65 to 1.78)            |
| 40–49.99                                    | 94 (5.3)     | 1.17 (0.75 to 1.83)| 1.24 (0.79 to 1.95)            |
| 50–59.99                                    | 135 (4.0)    | 0.89 (0.58 to 1.36)| 0.96 (0.62 to 1.49)            |
| 60–69.99                                    | 97 (1.9)     | 0.41 (0.26 to 0.64)| 0.49 (0.31 to 0.77)            |
| ≥70.00                                      | 47 (1.4)     | 0.30 (0.18 to 0.48)| 0.39 (0.24 to 0.64)            |
| **Sex**                                     |              |                   |                                 |
| Female                                      | 329 (3.1)    | 1.00              | 1.00                            |
| Male                                        | 117 (2.5)    | 0.82 (0.66 to 1.01)| 1.08 (0.86 to 1.34)            |
| **Ethnicity**                               |              |                   |                                 |
| Asian/Asian British                         | 18 (6.4)     | 2.39 (1.46 to 3.88)| 1.99 (1.20 to 3.30)            |
| Black/African/Caribbean/black British       | 6 (6.3)      | 2.32 (1.01 to 5.34)| 1.98 (0.84 to 4.65)            |
| Mixed/multiple/other ethnic groups          | 19 (4.7)     | 1.73 (1.08 to 2.78)| 1.40 (0.86 to 2.28)            |
| White                                       | 403 (2.8)    | 1.00              | 1.00                            |
| **Highest educational level attained**      |              |                   |                                 |
| Primary/secondary                           | 51 (3.1)     | 1.00              | 1.00                            |
| Higher/further (A levels)                   | 69 (3.1)     | 1.00 (0.69 to 1.44)| 0.86 (0.59 to 1.25)            |
| College                                     | 197 (2.9)    | 0.95 (0.69 to 1.29)| 0.75 (0.54 to 1.03)            |
| Postgraduate                                | 129 (2.8)    | 0.90 (0.65 to 1.25)| 0.62 (0.44 to 0.87)            |
| **Index of Multiple Deprivation rank, quartiles** |        |                   |                                 |
| Q1 (most deprived)                         | 131 (3.6)    | 1.30 (1.01 to 1.69)| 1.22 (0.93 to 1.60)            |
| Q2                                          | 108 (2.8)    | 1.02 (0.78 to 1.34)| 0.97 (0.73 to 1.28)            |
| Q3                                          | 97 (2.5)     | 0.90 (0.68 to 1.19)| 0.89 (0.67 to 1.19)            |
| Q4 (least deprived)                        | 107 (2.8)    | 1.00              | 1.00                            |
| **Household income sufficient for basic needs** |            |                   |                                 |
| Yes                                         | 416 (2.9)    | 1.00              | 1.00                            |
| Mostly/sometimes/no                        | 30 (3.0)     | 1.01 (0.69 to 1.47)| 0.85 (0.58 to 1.25)            |
| **Claiming universal credit**               |              |                   |                                 |
| No                                          | 425 (2.9)    | 1.00              | 1.00                            |
| Yes                                         | 19 (4.7)     | 1.65 (1.03 to 2.64)| 1.25 (0.77 to 2.03)            |
| **Housing**                                 |              |                   |                                 |
| Owns own home                               | 189 (2.0)    | 1.00              | 1.00                            |
| Mortgage                                    | 173 (4.6)    | 2.34 (1.90 to 2.89)| 1.34 (1.04 to 1.74)            |
| Privately renting                           | 40 (3.7)     | 1.88 (1.33 to 2.66)| 1.17 (0.79 to 1.73)            |
| Renting from council                        | 16 (3.4)     | 1.68 (1.00 to 2.82)| 1.20 (0.70 to 2.07)            |
| Others                                      | 28 (4.6)     | 2.33 (1.55 to 3.49)| 1.54 (0.95 to 2.49)            |
| **Frontline worker**                        |              |                   |                                 |
| No                                          | 276 (2.2)    | 1.00              | 1.00                            |
| Yes                                         | 90 (7.7)     | 3.69 (2.89 to 4.72)| 1.68 (1.28 to 2.21)            |
| **Shielding**                               |              |                   |                                 |
| No                                          | 423 (3.0)    | 1.00              | 1.00                            |
| Yes                                         | 23 (2.0)     | 1.65 (0.42 to 0.98)| 0.63 (0.41 to 0.97)            |
| **Number of people per bedroom**            |              |                   |                                 |
| ≥0.50                                       | 98 (1.7)     | 1.00              | 1.00                            |
| >0.50–0.99                                  | 110 (2.6)    | 1.58 (1.20 to 2.08)| 1.34 (1.01 to 1.78)            |
| 1–1.99                                      | 213 (4.5)    | 2.74 (2.15 to 3.49)| 1.91 (1.46 to 2.50)            |
| ≥2.00                                       | 19 (5.7)     | 3.54 (2.14 to 5.87)| 2.41 (1.40 to 4.13)            |
| **Any visits to/from other households in week prior to questionnaire completion** | |                   |                                 |
| No                                          | 202 (2.7)    | 1.00              | 1.00                            |
| Yes                                         | 244 (3.2)    | 1.21 (1.00 to 1.46)| 1.46 (1.19 to 1.80)            |
| **Preschool children (0–4 years old) at home with participant** | |                   |                                 |
| No                                          | 416 (2.8)    | 1.00              | 1.00                            |
| Yes                                         | 30 (5.9)     | 2.15 (1.47 to 3.15)| 1.19 (0.77 to 1.84)            |
| **Schoolchildren (5–15 years old) at home with participant** | |                   |                                 |
| No                                          | 351 (2.6)    | 1.00              | 1.00                            |
| Yes                                         | 95 (5.5)     | 2.18 (1.73 to 2.75)| 1.42 (1.08 to 1.87)            |
| **Working-age adult (16–64 years old) at home with participant** | |                   |                                 |
| No                                          | 117 (1.6)    | 1.00              | 1.00                            |
| Yes                                         | 329 (4.2)    | 2.74 (2.21 to 3.39)| 1.86 (1.45 to 2.41)            |
| **Number of different generations in household** | |                   |                                 |
| Living alone                                | 46 (1.6)     | 1.00              | 1.00                            |
| Single generation                           | 230 (2.8)    | 1.78 (1.29 to 2.45)| 1.66 (1.19 to 2.30)            |
| Two generations                             | 164 (4.1)    | 2.62 (1.88 to 3.64)| 2.08 (1.48 to 2.94)            |
| Three generations                           | 6 (5.0)      | 3.27 (1.37 to 7.83)| 2.54 (1.04 to 6.23)            |

Continued
Table 2 Continued

| Variable                                                                 | Number (%) with incident test-confirmed COVID-19 | Total number | Crude OR (95% CI) | Minimally adjusted OR (95% CI)* |
|--------------------------------------------------------------------------|--------------------------------------------------|--------------|-------------------|----------------------------------|
| Cat at home                                                              | 344 (2.9)                                        | 15215        | 1.00              | 1.00                             |
| Dog at home                                                              | 102 (3.1)                                        | 317 (2.7)    | 1.00              | 1.00                             |
| Number of public transport journeys in week prior to questionnaire completion | 35 (3.0)                                         | 129 (3.6)    | 1.00              | 1.33 (1.08 to 1.64)              |
| Travel to work/study in week prior to questionnaire completion           | 37 (2.5)                                         | 318 (3.8)    | 1.00              | 1.54 (1.09 to 2.18)              |
| Not currently working or studying                                        | 88 (1.7)                                         | 1.00         | 0.68 (0.46 to 1.00)| 1.20 (0.79 to 1.81)             |
| Number of visits to shops and other indoor public places in week prior to questionnaire completion | 33 (1.5)                                         | 15207        | 1.00              | 1.00                             |
| Tobacco smoking status                                                   | 247 (2.9)                                        | 15227        | 1.00              | 2.05 (1.40 to 2.98)              |
| Regular exposure to environmental tobacco smoke at home or in car        | 165 (2.8)                                        | 118 (3.3)    | 0.97 (0.80 to 1.19)| 2.23 (1.51 to 3.29)             |
| Vaping status                                                            | 34 (4.1)                                         | 1.00         | 1.42 (0.99 to 2.05)| 2.77 (1.85 to 4.14)             |
| Alcohol consumption in week prior to questionnaire completion, units     | 433 (2.9)                                        | 15226        | 1.00              | 2.16 (1.48 to 3.17)              |
| Vaping status                                                            | 13 (3.9)                                         | 1.00         | 1.35 (0.77 to 2.37)| 3.38 (2.25 to 5.07)             |
| Alcohol consumption in week prior to questionnaire completion, units     | 410 (2.9)                                        | 15185        | 1.00              | 1.40 (0.88 to 2.24)              |
| Vaping status                                                            | 16 (3.2)                                         | 1.00         | 1.12 (0.67 to 1.86)| 1.66 (0.62 to 2.09)             |
| Alcohol consumption in week prior to questionnaire completion, units     | 19 (4.0)                                         | 1.00         | 1.40 (0.88 to 2.24)| 1.69 (1.04 to 2.76)             |
| Hours of vigorous physical exercise in week prior to questionnaire completion | 171 (2.9)                                        | 15176        | 1.00              | 0.98 (0.79 to 1.22)              |
| Hours of light physical exercise in week prior to questionnaire completion | 163 (2.9)                                        | 109 (2.9)    | 0.98 (0.79 to 1.27)| 0.95 (0.75 to 1.18)             |
| Hours of lower impact physical activity in week prior to questionnaire completion | 189 (3.6)                                        | 15192        | 1.00              | 0.99 (0.78 to 1.27)              |
| Estimated average hours of sleep per night in month prior to questionnaire completion | 140 (2.8)                                        | 117 (2.4)    | 0.99 (0.78 to 1.27)| 1.03 (0.80 to 1.32)             |
| ≤6                                                                       | 41 (3.1)                                         | 15223        | 1.00              | 0.64 (0.51 to 0.81)              |
| 7                                                                        | 113 (3.1)                                        | 1.00         | 0.76 (0.61 to 0.95)| 0.87 (0.69 to 1.10)             |
| ≥9                                                                       | 133 (3.3)                                        | 1.00         | 0.64 (0.51 to 0.81)| 0.89 (0.70 to 1.14)             |
| ≤6                                                                       | 274 (3.1)                                        | 15176        | 1.00              | 0.64 (0.51 to 0.81)              |
| 7                                                                        | 88 (3.1)                                         | 1.00         | 0.97 (0.76 to 1.24)| 0.90 (0.70 to 1.16)             |
| ≥2                                                                       | 83 (3.3)                                         | 1.00         | 0.73 (0.57 to 0.94)| 0.76 (0.59 to 0.98)             |
| ≤6                                                                       | 41 (3.1)                                         | 1.00         | 0.76 (0.61 to 0.95)| 0.87 (0.69 to 1.10)             |
| 7                                                                        | 113 (3.1)                                        | 1.00         | 0.64 (0.51 to 0.81)| 0.89 (0.70 to 1.14)             |
| ≥9                                                                       | 133 (3.3)                                        | 1.00         | 0.64 (0.51 to 0.81)| 0.89 (0.70 to 1.14)             |

Minimally adjusted ORs (95% CI) with a p value of <0.10 are emboldened.

*Adjusted for age, sex, duration of participation and test frequency.

†Defined as exercise of sufficient intensity to make the participant breathless or to raise their heart rate significantly, such as heavy physical work, strenuous gardening (eg, vigorous digging, landscaping), swimming, jogging, aerobics, football, tennis, cycling and gym workouts, reported to the nearest hour.

‡Defined as exercise that did not make the participant breathless, such as walking for pleasure or exercise, walking to the shops and walking to work, reported to the nearest hour.

§Defined as exercise to improve flexibility or core strength such as yoga, tai chi or Pilates, reported to the nearest hour.

¶Reported to the nearest hour.
Table 3  Underlying conditions, medication use, vaccination status and risk of test-confirmed COVID-19: crude and minimally adjusted ORs

| Underlying conditions                        | Number (%) with incident test-confirmed COVID-19 | Total number | Crude OR (95% CI) | Minimally adjusted OR (95% CI)* |
|---------------------------------------------|-------------------------------------------------|--------------|-------------------|---------------------------------|
| Self-rated general health                   |                                                 |              |                   |                                 |
| Excellent                                   | 89 (2.8)                                        | 15 225       | 1.00              | 1.00                            |
| Very good                                   | 174 (2.9)                                       | 15 225       | 1.00 (0.77 to 1.29)| 1.06 (0.81 to 1.38)             |
| Good                                        | 120 (3.0)                                       | 15 225       | 1.02 (0.77 to 1.35)| 1.03 (0.77 to 1.37)             |
| Fair                                        | 52 (3.2)                                        | 15 225       | 1.10 (0.78 to 1.56)| 0.99 (0.70 to 1.42)             |
| Poor                                        | 11 (2.4)                                        | 15 225       | 0.84 (0.45 to 1.59)| 0.75 (0.40 to 1.43)             |
| Self-rated anxiety or depression            |                                                 |              |                   |                                 |
| No                                          | 316 (2.8)                                       | 15 216       | 1.00              | 1.00                            |
| Yes                                         | 130 (3.2)                                       | 15 216       | 1.13 (0.92 to 1.39)| 0.91 (0.73 to 1.12)             |
| Body mass index, kg/m²                       |                                                 |              |                   |                                 |
| <25                                         | 177 (2.4)                                       | 15 189       | 1.00              | 1.00                            |
| 25–30                                       | 168 (3.5)                                       | 15 189       | 1.48 (1.19 to 1.83)| 1.58 (1.27 to 1.97)             |
| >30                                         | 100 (3.4)                                       | 15 189       | 1.45 (1.13 to 1.86)| 1.37 (1.06 to 1.77)             |
| Asthma                                      |                                                 |              |                   |                                 |
| No                                          | 384 (3.0)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 62 (2.5)                                        | 15 227       | 0.82 (0.62 to 1.07)| 0.67 (0.51 to 0.88)             |
| Atopic disease†                             |                                                 |              |                   |                                 |
| No                                          | 349 (3.1)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 97 (2.5)                                        | 15 227       | 0.80 (0.64 to 1.01)| 0.65 (0.51 to 0.82)             |
| Diabetic status                             |                                                 |              |                   |                                 |
| No diabetes                                 | 415 (3.0)                                       | 15 206       | 1.00              | 1.00                            |
| Pre-diabetes                                | 14 (3.1)                                        | 15 206       | 1.06 (0.62 to 1.82)| 1.38 (0.79 to 2.41)             |
| Type 1 diabetes                             | 3 (2.8)                                         | 15 206       | 0.96 (0.30 to 3.02)| 0.81 (0.25 to 2.62)             |
| Type 2 diabetes                             | 13 (2.1)                                        | 15 206       | 0.70 (0.40 to 1.22)| 0.92 (0.52 to 1.62)             |
| Heart disease‡                              |                                                 |              |                   |                                 |
| No                                          | 432 (3.0)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 14 (2.4)                                        | 15 227       | 0.80 (0.47 to 1.38)| 1.28 (0.73 to 2.25)             |
| Arterial disease§                           |                                                 |              |                   |                                 |
| No                                          | 431 (3.0)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 15 (1.9)                                        | 15 227       | 0.63 (0.38 to 1.07)| 0.91 (0.53 to 1.57)             |
| Hypertension                                |                                                 |              |                   |                                 |
| No                                          | 378 (3.2)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 68 (2.1)                                        | 15 227       | 0.64 (0.50 to 0.84)| 0.88 (0.67 to 1.17)             |
| Kidney disease                              |                                                 |              |                   |                                 |
| No                                          | 441 (3.0)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 5 (1.6)                                         | 15 227       | 0.54 (0.22 to 1.31)| 0.62 (0.25 to 1.52)             |
| Major neurological conditions¶              |                                                 |              |                   |                                 |
| No                                          | 440 (3.0)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 6 (1.5)                                         | 15 227       | 0.50 (0.22 to 1.12)| 0.62 (0.27 to 1.41)             |
| Cancer                                      |                                                 |              |                   |                                 |
| Never                                       | 410 (3.0)                                       | 15 227       | 1.00              | 1.00                            |
| Past (cured or in remission)                | 33 (2.6)                                        | 15 227       | 0.87 (0.61 to 1.25)| 1.12 (0.77 to 1.63)             |
| Present (active treatment in progress)      | 3 (2.2)                                         | 15 227       | 0.72 (0.23 to 2.27)| 0.89 (0.28 to 2.87)             |
| Immunodeficiency**                         |                                                 |              |                   |                                 |
| No                                          | 446 (2.9)                                       | 15 140       | 1.00              | 1.00                            |
| Yes                                         | 0 (0.0)                                         | 15 140       | Not applicable    | Not applicable                  |
| Periodontitis††                             |                                                 |              |                   |                                 |
| No                                          | 240 (2.7)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 129 (3.3)                                       | 15 227       | 1.20 (0.96 to 1.49)| 1.30 (1.04 to 1.62)             |
| Missing                                     | 77 (3.05)                                       |              |                   |                                 |
| Medications                                 |                                                 |              |                   |                                 |
| Statins                                     |                                                 |              |                   |                                 |
| No                                          | 398 (3.2)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 48 (1.8)                                        | 15 227       | 0.57 (0.42 to 0.77)| 0.93 (0.67 to 1.29)             |
| ACE inhibitors                              |                                                 |              |                   |                                 |
| No                                          | 415 (3.0)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 31 (2.1)                                        | 15 227       | 0.68 (0.47 to 0.99)| 0.90 (0.62 to 1.32)             |
| Proton pump inhibitors                      |                                                 |              |                   |                                 |
| No                                          | 395 (3.0)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 51 (2.4)                                        | 15 227       | 0.80 (0.60 to 1.08)| 0.88 (0.65 to 1.20)             |
| Inhaled corticosteroids                     |                                                 |              |                   |                                 |
| No                                          | 410 (3.0)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 36 (2.5)                                        | 15 227       | 0.83 (0.59 to 1.18)| 0.68 (0.48 to 0.97)             |
| Systemic immunosuppressants                 |                                                 |              |                   |                                 |
| No                                          | 437 (3.0)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 9 (1.3)                                         | 15 227       | 0.43 (0.22 to 0.84)| 0.39 (0.20 to 0.77)             |
| Selective serotonin reuptake inhibitors (SSRIs) |                                         |              |                   |                                 |
| No                                          | 401 (2.8)                                       | 15 227       | 1.00              | 1.00                            |
| Yes                                         | 45 (4.2)                                        | 15 227       | 1.50 (1.09 to 2.05)| 1.19 (0.86 to 1.64)             |

Holt H, et al. Thorax 2022;77:900–912. doi:10.1136/thoraxjnl-2021-217487

Continued
Role of the funding source
Barts Charity and Health Data Research UK had no role in study design, data analysis, data interpretation or writing of the report. MT, HH and MG had access to raw data. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.

RESULTS
Of the 17,558 participants who completed the COV IDENCE UK baseline questionnaire on or before 2 November 2020, we excluded those who were identified as already having had test-confirmed and/or symptom-defined probable COVID-19 (n=1477). Of the remaining 16,081 participants, 15,227 completed at least one subsequent monthly follow-up questionnaire at least 30 days after enrolment and were included in this prospective analysis; 14,348 completed the final follow-up questionnaire on or before 5 February 2021, giving a retention rate of 89.2% (online supplemental figure 1). Selected baseline characteristics of participants included in the prospective analysis are presented in table 1; their characteristics are compared with those who were excluded from this analysis in online supplemental table 3. Mean age of those contributing data to prospective analyses was 59.4 years (range 16.0–94.4 years), 69.8% were female and 94.9% identified their ethnic origin as white.

| Table 3 | Continued |
| Number (% with incident test-confirmed COVID-19 | Total number | Crude OR (95% CI) | Minimally adjusted OR (95% CI)* |
| --- | --- | --- | --- |
| Non-SSRI antidepressants | No | 424 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 22 (3.4) | 15,227 | 1.19 (0.77 to 1.84) | 1.17 (0.75 to 1.83) |
| Angiotensin receptor blockers | No | 427 (3.0) | 15,227 | 1.00 | 1.00 |
| | Yes | 19 (2.2) | 15,227 | 0.74 (0.46 to 1.17) | 1.01 (0.62 to 1.63) |
| Vitamin K antagonists | No | 444 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 2 (1.8) | 15,227 | 0.61 (0.15 to 2.46) | 0.73 (0.18 to 3.06) |
| Beta-blockers | No | 424 (3.0) | 15,227 | 1.00 | 1.00 |
| | Yes | 22 (2.0) | 15,227 | 0.67 (0.43 to 1.03) | 0.91 (0.59 to 1.43) |
| Thiazides | No | 437 (3.0) | 15,227 | 1.00 | 1.00 |
| | Yes | 9 (1.8) | 15,227 | 0.61 (0.31 to 1.19) | 0.81 (0.41 to 1.60) |
| H2-receptor antagonists | No | 442 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 4 (4.6) | 15,227 | 1.60 (0.59 to 4.39) | 1.36 (0.48 to 3.83) |
| Calcium channel blockers | No | 417 (3.0) | 15,227 | 1.00 | 1.00 |
| | Yes | 29 (2.0) | 15,227 | 0.64 (0.44 to 0.93) | 0.91 (0.61 to 1.36) |
| Inhaled bronchodilators† | No | 414 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 411 (2.7) | 15,227 | 0.84 (0.59 to 1.20) | 0.54 (0.31 to 0.94) |
| Non-steroidal anti-inflammatory drugs | No | 421 (3.0) | 15,227 | 1.00 | 1.00 |
| | Yes | 25 (2.0) | 15,227 | 0.66 (0.44 to 0.99) | 0.84 (0.55 to 1.28) |
| Sodium-glucose co-transporter-2 inhibitors | No | 442 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 2 (2.5) | 15,227 | 0.86 (0.21 to 3.51) | 0.95 (0.23 to 4.00) |
| Anti-platelet drugs | No | 422 (3.0) | 15,227 | 1.00 | 1.00 |
| | Yes | 24 (2.5) | 15,227 | 0.63 (0.55 to 1.26) | 1.29 (0.83 to 1.99) |
| Sex hormone therapy | No | 401 (2.8) | 15,227 | 1.00 | 1.00 |
| | Yes | 45 (4.6) | 15,227 | 1.44 (1.05 to 1.97) | 1.19 (0.85 to 1.65) |
| Paracetamol | No | 430 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 16 (2.5) | 15,227 | 0.84 (0.51 to 1.39) | 0.89 (0.53 to 1.50) |
| Metformin | No | 434 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 12 (2.8) | 15,227 | 0.94 (0.52 to 1.76) | 1.28 (0.71 to 2.31) |
| Bisphosphonates | No | 441 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 5 (1.9) | 15,227 | 0.65 (0.27 to 1.58) | 0.76 (0.31 to 1.90) |
| Vaccinations | | | | | |
| BCG-vaccinated | No | 40 (2.0) | 15,197 | 1.00 | 1.00 |
| | Yes | 366 (3.1) | 15,197 | 1.55 (1.12 to 2.16) | 1.36 (0.97 to 1.90) |
| | Unsure | 38 (3.5) | 15,197 | 1.23 (0.79 to 1.93) | 1.26 (0.80 to 2.00) |
| MMR-vaccinated | No | 131 (2.6) | 11,451 | 1.00 | 1.00 |
| | Yes | 226 (3.5) | 11,451 | 1.38 (1.11 to 1.71) | 1.04 (0.81 to 1.32) |

Minimally adjusted ORs (95% CI) with a p value of <0.10 are bold.
*Adjusted for age, sex, duration of participation and test frequency.
†Defined by atopic eczema/dermatitis and/or hayfever/allergic rhinitis.
‡Defined as coronary artery disease or heart failure.
§Defined as ischaemic heart disease, peripheral vascular disease or cerebrovascular disease.
¶Defined as stroke, transient ischaemic attack, dementia, Parkinson’s disease, multiple sclerosis or motor neuron disease.
**Defined as HIV, primary immune deficiency or other immunodeficiency.
††Defined as being present if participant answered ‘yes’ to any of the three questions relating to gum disease/dental health listed in online supplemental table 2.
‡‡Defined as β2 adrenoceptor agonists or anticholinergics.

MMR, measles, mumps and rubella.

Holt H, et al. Thorax 2022;77:900–912. doi:10.1136/thoraxjnl-2021-217487
### Table 4  
Diet, supplemental micronutrient intake and risk of test-confirmed COVID-19: crude and minimally adjusted ORs

| Diet | Number (%) with incident test-confirmed COVID-19 | Total number | Crude OR (95% CI) | Minimally adjusted OR (95% CI)* |
|------|-----------------------------------------------|--------------|-------------------|-------------------------------|
| Dietary restrictions | None | 419 (2.9) | 15,227 | 1.00 | 1.00 |
| | Vegetarian | 22 (3.2) | 15,227 | 1.11 (0.72 to 1.72) | 0.89 (0.57 to 1.40) |
| | Vegan‡ | 5 (2.2) | 15,227 | 0.75 (0.31 to 1.83) | 0.60 (0.24 to 1.49) |
| Number of portions of fruit, vegetables and salad intake per day in week prior to questionnaire completion, quartiles | Q1 | 78 (3.5) | 15,227 | 1.00 | 1.00 |
| | Q2 | 158 (3.1) | 15,227 | 0.88 (0.67 to 1.17) | 0.90 (0.68 to 1.20) |
| | Q3 | 87 (3.0) | 15,227 | 0.85 (0.62 to 1.16) | 0.89 (0.64 to 1.22) |
| | Q4 | 120 (2.4) | 15,227 | 0.66 (0.49 to 0.88) | 0.73 (0.54 to 0.99) |
| Number of portions of dairy products per day in week prior to questionnaire completion | 0–1 | 114 (2.8) | 15,227 | 1.00 | 1.00 |
| | 2 | 142 (3.2) | 15,227 | 1.15 (0.90 to 1.48) | 1.18 (0.91 to 1.53) |
| | 3–5 | 99 (2.7) | 15,227 | 0.96 (0.73 to 1.27) | 1.06 (0.80 to 1.41) |
| | ≥6 | 91 (2.9) | 15,227 | 1.03 (0.78 to 1.37) | 1.24 (0.93 to 1.65) |
| Total number of portions of fish (oily or white) intake in the week prior to questionnaire completion | Q1 | 94 (3.8) | 15,227 | 1.00 | 1.00 |
| | Q2 | 79 (3.2) | 15,227 | 0.85 (0.63 to 1.15) | 0.99 (0.73 to 1.36) |
| | Q3 | 111 (2.7) | 15,227 | 0.71 (0.53 to 0.93) | 0.88 (0.66 to 1.18) |
| | Q4 | 162 (2.6) | 15,227 | 0.66 (0.49 to 0.88) | 0.73 (0.54 to 0.99) |
| Portions of oily fish intake in the week prior to questionnaire completion | 0 | 210 (3.7) | 15,227 | 1.00 | 1.00 |
| | 1 | 133 (2.7) | 15,227 | 0.72 (0.58 to 0.90) | 0.86 (0.69 to 1.08) |
| | 2 | 71 (2.4) | 15,227 | 0.64 (0.49 to 0.85) | 0.80 (0.60 to 1.06) |
| | ≥3 | 32 (2.1) | 15,227 | 0.57 (0.39 to 0.83) | 0.76 (0.52 to 1.13) |
| Portions of white fish intake in the week prior to questionnaire completion | 0 | 131 (3.3) | 15,227 | 1.00 | 1.00 |
| | 1 | 170 (2.8) | 15,227 | 0.83 (0.66 to 1.04) | 0.99 (0.78 to 1.26) |
| | 2 | 92 (2.6) | 15,227 | 0.76 (0.58 to 1.00) | 0.95 (0.72 to 1.26) |
| | ≥3 | 53 (3.3) | 15,227 | 0.98 (0.71 to 1.35) | 1.16 (0.83 to 1.61) |
| Number of cups of non-alcoholic fluids per day in the week prior to questionnaire completion, quartiles | Q1 | 104 (3.0) | 15,227 | 1.00 | 1.00 |
| | Q2 | 75 (2.9) | 15,227 | 0.98 (0.73 to 1.28) | 1.03 (0.76 to 1.41) |
| | Q3 | 116 (2.5) | 15,227 | 0.84 (0.64 to 1.07) | 0.91 (0.62 to 1.07) |
| | Q4 | 149 (3.4) | 15,227 | 1.14 (0.88 to 1.47) | 0.99 (0.76 to 1.29) |
| Micronutrient supplement use | Multivitamin supplement | No | 331 (2.7) | 15,227 | 1.00 | 1.00 |
| | Yes | 115 (3.6) | 15,227 | 1.33 (1.07 to 1.65) | 1.12 (0.89 to 1.40) |
| | Vitamin A supplement | No | 445 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 1 (1.1) | 15,227 | 0.38 (0.05 to 2.73) | 0.43 (0.06 to 3.15) |
| | Vitamin C supplement | No | 397 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 49 (3.1) | 15,227 | 1.09 (0.80 to 1.47) | 1.03 (0.76 to 1.41) |
| | Vitamin D supplement | No | 305 (3.2) | 15,227 | 1.00 | 1.00 |
| | Yes | 141 (2.5) | 15,227 | 0.80 (0.65 to 0.98) | 0.80 (0.65 to 0.99) |
| | Zinc supplement | No | 425 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 21 (2.8) | 15,227 | 0.97 (0.62 to 1.51) | 0.93 (0.58 to 1.46) |
| | Iron supplement | No | 423 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 23 (4.6) | 15,227 | 1.63 (1.06 to 2.51) | 1.27 (0.82 to 1.98) |
| | Probiotic supplement | No | 426 (3.0) | 15,227 | 1.00 | 1.00 |
| | Yes | 20 (2.2) | 15,227 | 0.72 (0.46 to 1.13) | 0.69 (0.44 to 1.10) |
| | Fish oil, krill oil or other omega-3 supplements | No | 400 (3.0) | 15,227 | 1.00 | 1.00 |
| | Yes | 46 (2.7) | 15,227 | 0.91 (0.67 to 1.25) | 0.98 (0.71 to 1.35) |
| | Cod liver oil supplement | No | 409 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 37 (3.0) | 15,227 | 1.03 (0.73 to 1.45) | 1.29 (0.91 to 1.84) |
| | Garlic or garlic powder (allicin) supplement | No | 439 (2.9) | 15,227 | 1.00 | 1.00 |
| | Yes | 7 (2.3) | 15,227 | 0.77 (0.36 to 1.63) | 0.93 (0.43 to 2.02) |
| | Selenium supplement | No | 445 (3.0) | 15,227 | 1.00 | 1.00 |
| | Yes | 1 (0.6) | 15,227 | 0.21 (0.03 to 1.47) | 0.20 (0.03 to 1.46) |

Minimally adjusted ORs (95% CI) with a p value of <0.10 are emboldened.
*Adjusted for age, sex, duration of participation and test frequency.
†Defined as excluding meat and fish, but not eggs or cow’s milk, from the diet.
‡Defined as excluding meat, fish, eggs and cow's milk from the diet.

Holt H, et al. Thorax 2022;77:900–912. doi:10.1136/thoraxjnl-2021-217487
Table 5  Independent risk factors for test-confirmed COVID-19: final multivariable model (n=14556)

| Characteristic                                      | Categories                  | Fully adjusted OR (95% CI)* | P for trend | E₁₆₀ (E₀) |
|-----------------------------------------------------|-----------------------------|-----------------------------|-------------|-----------|
| Age, years                                          | 16–29.99                    | 1.00                        | 0.08        |           |
|                                                     | 30–39.99                    | 1.20 (0.68 to 2.12)         |             |           |
|                                                     | 40–49.99                    | 1.20 (0.69 to 2.10)         |             |           |
|                                                     | 50–59.99                    | 1.12 (0.65 to 1.93)         |             |           |
|                                                     | 60–69.99                    | 0.80 (0.44 to 1.44)         |             |           |
|                                                     | ≥70.00                      | 0.74 (0.39 to 1.41)         |             |           |
| Sex                                                 | Female                      | 1.00                        | 0.97 (0.76 to 1.23) | 3.99 (1.99) |
|                                                     | Male                        |                             |             |           |
| Ethnicity                                           | Asian/Asian British         | 2.28 (1.33 to 3.91)         | —           |           |
|                                                     | Black/African/Caribbean/Black British | 1.84 (0.70 to 4.82) |             |           |
|                                                     | Mixed/multiple/other ethnic groups | 1.53 (0.92 to 2.53) |             |           |
|                                                     | White                       | 1.00                        |             |           |
| Highest educational level attained                  | Primary/secondary           | 1.00                        | 0.08        |           |
|                                                     | Higher/further (A levels)   | 0.90 (0.61 to 1.33)         |             |           |
|                                                     | College                     | 0.82 (0.58 to 1.15)         |             |           |
|                                                     | Postgraduate                | 0.74 (0.51 to 1.07)         |             |           |
| Index of Multiple Deprivation (IMD) rank, quartiles | Q1 (most deprived)         | 1.11 (0.84 to 1.48)         | 0.44        |           |
|                                                     | Q2                          | 0.90 (0.67 to 1.20)         |             |           |
|                                                     | Q3                          | 0.87 (0.65 to 1.16)         |             |           |
|                                                     | Q4 (least deprived)         | 1.00                        |             |           |
| Housing                                             | Owns own home               | 1.00                        |             |           |
|                                                     | Mortgage                    | 1.19 (0.91 to 1.56)         |             |           |
|                                                     | Privately renting           | 0.96 (0.63 to 1.46)         |             |           |
|                                                     | Renting from council        | 0.96 (0.53 to 1.74)         |             |           |
|                                                     | Others                      | 1.34 (0.81 to 2.21)         |             |           |
| Number of people per bedroom†                       | ≤0.50                       | 1.00                        | <0.001      |           |
|                                                     | >0.50–0.99                  | 1.24 (0.93 to 1.66)         |             |           |
|                                                     | 1.00–1.99                   | 1.67 (1.25 to 2.23)         | 2.73 (1.81) |           |
|                                                     | ≥2.00                       | 2.04 (1.15 to 3.60)         | 3.52 (1.43) |           |
| Schoolchildren (aged 5–15 years) at home with participant | No                          | 1.00                        |             |           |
|                                                     | Yes                         | 1.16 (0.86 to 1.56)         |             |           |
| Dog at home                                         | No                          | 1.00                        |             |           |
|                                                     | Yes                         | 1.17 (0.93 to 1.47)         |             |           |
| Shielding                                           | No                          | 1.00                        |             |           |
|                                                     | Yes                         | 1.04 (0.64 to 1.68)         |             |           |
| Any visits to/from other households in week prior to questionnaire completion | No                          | 1.00                        |             |           |
|                                                     | Yes                         | 1.31 (1.06 to 1.62)         | 1.95 (1.31) |           |
| Number of visits to shops and other indoor public places in week prior to questionnaire completion† | Q1                          | 1.00                        | <0.001      |           |
|                                                     | Q2                          | 1.96 (1.29 to 2.98)         |             |           |
|                                                     | Q3                          | 2.21 (1.43 to 3.43)         |             |           |
|                                                     | Q4                          | 2.63 (1.69 to 4.10)         |             |           |
| Travel to work/study in week prior to questionnaire completion | No                          | 1.00                        |             |           |
|                                                     | Yes                         | 1.36 (0.93 to 1.99)         |             |           |
|                                                     | Not currently working or studying | 1.27 (0.82 to 1.95)       |             |           |
| Frontline worker                                     | No                          | 1.00                        |             |           |
|                                                     | Health or social care worker | 1.35 (1.00 to 1.82)        | 2.04 (1.02) |           |
|                                                     | Other frontline worker       | 1.49 (1.12 to 1.98)         | 2.34 (1.49) |           |
| Number of portions of fruit, vegetables and salad intake per day in week prior to questionnaire completion, quartiles | Q1                          | 1.00                        | 0.31        |           |
|                                                     | Q2                          | 1.00 (0.75 to 1.35)         |             |           |
|                                                     | Q3                          | 1.04 (0.74 to 1.45)         |             |           |
|                                                     | Q4                          | 0.86 (0.63 to 1.19)         |             |           |

Continued
The geographical distribution of COVIDENCE UK participants aligned closely with that of incident COVID-19 in the UK (online supplemental figure 2).

A total of 446 participants experienced at least one episode of PCR-confirmed or lateral flow test-confirmed COVID-19 during 2,619,921 person-days of follow-up, of whom 32 were hospitalised. We calculated crude and minimally adjusted ORs (aORs) for associations between risk of test-confirmed COVID-19 and sociodemographic, occupational and lifestyle factors (table 2); long-standing conditions, medication use and vaccination status (table 3); and diet and supplemental micronutrient intake (table 4). After adjustment for age, sex, duration of participation and testing frequency ("minimal adjustment"), the following factors were found to associate with increased odds of COVID-19 with \( p < 0.10 \): Asian/Asian British versus white ethnic origin, housing type (paying mortgage and ‘other’ vs owning own home), frontline versus

### Table 5 Continued

| Characteristic | Categories | Fully adjusted OR (95% CI)* | P for trend | E_v (E_w) |
|----------------|------------|----------------------------|-------------|----------|
| **Taking vitamin D supplement** | No | 1.00 | | |
| | Yes | 0.93 (0.75 to 1.16) | | |
| **Hours of lower impact physical activity in week prior to questionnaire completion§** | 0 | 1.00 | 0.22 | |
| | 1 | 1.01 (0.78 to 1.31) | | |
| | ≥2 | 0.83 (0.63 to 1.09) | | |
| **Estimated average hours of sleep per night in month prior to questionnaire completion¶** | 6 | 1.14 (0.79 to 1.65) | 0.31** | |
| | 7 | 1.14 (0.88 to 1.48) | | |
| | 8 | 1.00 | | |
| | ≥9 | 1.29 (1.01 to 1.66) | 1.90 (1.11) | |
| **Alcohol consumption in week prior to questionnaire completion, units** | None | 1.00 | 0.39 | |
| | 1–7 | 1.11 (0.85 to 1.44) | | |
| | 8–14 | 1.08 (0.79 to 1.47) | | |
| | 15–21 | 1.45 (1.01 to 2.08) | | |
| | 22–28 | 1.23 (0.72 to 2.11) | | |
| | ≥28 | 0.83 (0.43 to 1.60) | | |
| **Body mass index, kg/m²** | <25 | 1.00 | 0.004 | |
| | 25–30 | 1.50 (1.19 to 1.89) | 2.37 (1.67) | |
| | ≥30 | 1.39 (1.06 to 1.84) | 2.13 (1.31) | |
| **Asthma** | No | 1.00 | | |
| | Yes | 0.82 (0.55 to 1.24) | | |
| **Atopic disease††** | No | 1.00 | | |
| | Yes | 0.75 (0.59 to 0.97) | 2.00 (1.21) | |
| **Periodontitis‡‡** | No | 1.00 | | |
| | Yes | 1.20 (0.95 to 1.52) | | |
| **Systemic immunosuppressants** | No | 1.00 | | |
| | Yes | 0.47 (0.22 to 0.99) | 3.68 (1.11) | |
| **Inhaled corticosteroids** | No | 1.00 | | |
| | Yes | 1.01 (0.55 to 1.84) | | |
| **Inhaled bronchodilators§§** | No | 1.00 | | |
| | Yes | 1.07 (0.61 to 1.88) | | |
| **BCG-vaccinated** | No | 1.00 | | |
| | Yes | 1.38 (0.97 to 1.96) | | |
| | Unsure | 1.24 (0.78 to 1.99) | | |
| **Duration of participation, days** | 1.00 (1.00 to 1.00) | | | |
| **Swab test frequency** | 1.62 (1.52 to 1.72) | | | |

*Adjusted for age, sex, duration of participation, test frequency, ethnicity, highest educational level attained, IMD rank, hours of sleep per night, housing, number of people per bedroom, presence of schoolchildren at home, dog at home, shielding, visits to other households, visits to shops and other indoor places, travel to work or study, front line worker status, fruit, vegetable and salad intake, supplement vitamin D intake, low-impact physical activity, alcohol intake, body mass index, history of asthma, history of atopic disease, use of systemic immunosuppressants, use of inhaled corticosteroids, use of inhaled bronchodilators and BCG vaccination status.

†Adjusted OR per additional 0.5 people per bedroom 1.26 (95% CI 1.11 to 1.43).

‡Adjusted OR per extra visit per week 1.05 (95% CI 1.02 to 1.09).

§Defined as exercise to improve flexibility or core strength such as yoga, tai chi or Pilates, reported to the nearest hour.

¶Reported to the nearest hour.

**Only applies to sleeping categories below 8 hours.

††Defined as being present if participant answered ‘yes’ to any of the three questions relating to gum disease/dental health listed in online supplemental table 2.

‡‡Defined as being present if participant answered ‘yes’ to any of the three questions relating to gum disease/dental health listed in online supplemental table 2.

§§Defined as β2 adrenoceptor agonists or anticholinergics.

E_v, E-w, E-value for 95% CI; E_w, E-value for point estimate.
non-frontline worker status, household overcrowding (>0.5 vs ≤0.5 people per bedroom), any visit versus no visits to/from other households in the previous week, presence versus absence of schoolchildren and working-age adults in the household, living with others versus living alone, periodontitis, having versus not having a dog at home, any versus no travel to work or place of study in the week preceding questionnaire completion, number of visits to shops or other indoor public places per week (quartiles 2, 3, 4 vs quartile 1), alcohol consumption (15–21 vs 0/week), sleep duration (7 or ≥9 vs 8 hours/night), raised body mass index (BMI) (>25.0 vs ≤25.0 kg/m²) and history versus no history of BCG vaccination. The following factors associated with decreased odds of COVID-19 with p<0.10 after minimal adjustment: age ≥60 vs 16–29.99 years, education to college or postgraduate level versus primary/secondary level, shielding versus non-shielding, low-impact physical activity (≥2 vs 0 hours/week), presence versus absence of asthma diagnosis, presence versus absence of atopic disease (defined by atopic eczema/dermatitis and/or hayfever/allergic rhinitis), use versus no use of systemic immunosuppressants, inhaled corticosteroids and bronchodilators (defined as β-2 adrenoreceptor agonists or anticholinergics), higher intake of fruit and vegetables (top vs bottom quartiles) and use versus no use of vitamin D supplements.

All factors associating with test-confirmed COVID-19 with p<0.10 in the minimally adjusted model were then assessed for collinearity: the resultant heat map (online supplemental figure 3) revealed a high degree of collinearity between the number of working-age adults in the household, multigenerational households and number of people per bedroom. Since household overcrowding (as indicated by number of people per bedroom) was deemed to relate most closely to SARS-CoV-2 exposure risk from a clinical/epidemiological perspective, the other two independent variables were excluded from the multivariable model.

Table 5 presents fully adjusted ORs for associations between potential risk factors for test-confirmed COVID-19. The final multivariable model adjusted mutually for age, sex, duration of participation, test frequency, ethnicity, highest educational level attained, Index of Multiple Deprivation rank, household income, housing type, number of people per bedroom, presence of schoolchildren at home, presence of a dog in the household, shielding, visits to/from other households, visits to shops and other indoor places, travel to work or study, frontline worker status, low-impact physical activity, alcohol intake, BMI, history of asthma, history of atopic disease, use of systemic immunosuppressants, use of inhaled corticosteroids, use of bronchodilators, BCG vaccination status, intake of fruit, vegetables and salads, and intake of supplemental vitamin D. Increased odds of developing COVID-19 were independently associated with Asian/Asian British versus white ethnicity (aOR 2.28, 95% CI 1.33 to 3.91), household overcrowding (aOR per additional 0.5 people/bedroom 1.26, 1.11 to 1.43), any versus no visits to/from other households, visits to shops and other indoor places, travel to work or study, frontline worker status, low-impact physical activity, alcohol intake, BMI, history of asthma, history of atopic disease, use of systemic immunosuppressants, use of inhaled corticosteroids, use of bronchodilators, BCG vaccination status, intake of fruit, vegetables and salads, and intake of supplemental vitamin D.

We performed two sensitivity analyses to explore the robustness of the multivariable results. The first (online supplemental table 4) excluded 3202 participants who received one or more doses of COVID-19 vaccine before the date of the data download (5 February 2021). The second (online supplemental table 5) excluded 3813 participants who commenced vitamin D supplements after enrolment in the cohort due to participation in a clinical trial. Both analyses yielded similar findings to those presented above. An exploratory analysis to determine whether COVID-19 risk differed for participants with atopic versus non-atopic asthma endotypes (as defined by the presence or absence of atopic eczema/dermatitis and/or hayfever/allergic rhinitis) showed reduced odds of COVID-19 for participants with atopic asthma (aOR 0.62, 0.41 to 0.93), but not for those with non-atopic asthma (aOR 0.88, 0.60 to 1.30), as compared with participants without atopic disease or asthma. These effect estimates did not materially change after further adjustment for inhaled corticosteroids (online supplemental table 6).

We then proceeded to investigate determinants of symptom-defined probable COVID-19, with casehood ascribed using an algorithm published by Menzi et al.16 In the subset of 6035 COV-IDENCE UK participants entering the prospective analysis who had one or more tests for COVID-19 during the follow-up period, this case definition had sensitivity and specificity for test-confirmed COVID-19 of 0.47 and 0.97, respectively, with an area under the receiver operating characteristic curve of 0.72 (95% CI 0.69 to 0.74; online supplemental table 7). Potential risk factors associating with probable symptom-defined COVID-19 with p<0.10 in a minimally adjusted model (ie, adjusting for age, sex and duration of participation) were included in the multivariable model presented in online supplemental table 8. Increased risk of probable symptom-defined COVID-19 was independently associated with Asian/Asian British versus white ethnicity, housing type (having a mortgage vs home ownership), household overcrowding (>1.0 vs ≤0.5 people per bedroom), health or social care occupation, use of cod liver oil supplements, poorer self-assessed general health, periodontitis and use of selective serotonin reuptake inhibitors, while lower risk of probable symptom-defined COVID-19 was independently associated with greater age (≥50 vs 16–29.99 years).

DISCUSSION

In this large, prospective population-based study evaluating a diverse array of potential risk factors for developing COVID-19, we found that Asian/Asian British ethnicity, household overcrowding, indoor social mixing, employment as a frontline worker outside of health and social care, and being overweight or obese were all independently associated with an increased risk of test-confirmed COVID-19. Associations with household overcrowding and visits to indoor public places showed dose-response relationships, strengthening causal inference. History of atopic disease and use of systemic immunosuppressant medication were independently associated with decreased risk of test-positive disease. No statistically significant independent associations with disease risk were seen for other factors investigated, including age, sex, diet, supplemental micronutrient intake, and other long-standing conditions and medications.

This study sheds new light on the degree of overlap between risk factors for developing COVID-19 (irrespective of severity) versus risk factors for developing severe or fatal disease specifically. Our finding that people of Asian/Asian British ethnic origin are at increased risk of developing COVID-19 is consistent with reports of increased susceptibility and disease severity in this group.7,10 One limitation of previous studies investigating ethnic variation in COVID-19 risk is that they did not adjust for behaviours influencing SARS-CoV-2 exposure, such as visits to other households and indoor public places. In our study, increased risk of developing COVID-19 in people of Asian/Asian British ethnic origin is significantly greater than that seen in other ethnic groups, particularly in younger age groups.
was not explained by such behaviours, nor by social deprivation, domestic overcrowding, occupation, BMI or comorbidities. There is therefore an urgent need for further research to investigate social and biological factors that might explain ethnic disparities in risk of developing COVID-19, including vitamin D deficiency.\(^9\) The association between raised BMI and increased susceptibility to COVID-19 that we found is consistent with studies identifying obesity as a risk factor for both susceptibility to, and severe outcomes of, COVID-19.\(^4\)\(^9\)\(^20\)

By contrast, a number of established risk factors for severe and fatal disease, including older age, male sex and underlying conditions such as diabetes, heart disease, COPD and hypertension, were not associated with risk of developing COVID-19 in our study, where cases were predominantly mild (93.1\% non-hospitalised). Our finding of no association between kidney disease and susceptibility to COVID-19 contrasts with that of de Lusignan \textit{et al.},\(^22\) who reported such an association in a study that was conducted earlier in the UK pandemic when testing was limited to those with more severe COVID-19 illness presenting to hospital. The bias resulting from focusing testing on more severe disease in that study may have contributed to the different findings in our study, which was conducted over a later period when testing was more widely available. In contrast with other studies,\(^22\)\(^23\) we found no association between intake of micronutrient supplements and protection against COVID-19: this may reflect a false-negative result from our study (arising due to a relative lack of power to detect modest protective effects), or a false-positive result from other studies arising as a result of less rigorous adjustment for potential socioeconomic confounding.

In keeping with reports from the UK\(^7\) and elsewhere,\(^9\) we found younger age to be associated with increased risk of developing COVID-19 in crude and minimally adjusted models. However, this association did not persist after adjustment for multiple potential confounders, including behaviours related to social mixing, suggesting that lower incidence of COVID-19 in older adults in our study may be explained by reductions in social contact. We did not see a difference in disease risk for people with diabetes, heart disease or hypertension. While this contrasts with a study reporting lower prevalence of SARS-CoV-2 seropositivity among people with these underlying conditions, that study did not adjust, as we did, for behaviours influencing exposure to infection.\(^7\) The only long-standing conditions associated with disease risk in our study were atopic diseases, which were associated with reduced risk of disease, particularly among those who also had asthma. This may reflect decreased expression of ACE2, the gene encoding the SARS-CoV-2 receptor, which has been reported in people with both high levels of allergic sensitisation and asthma.\(^17\)

Our study has several strengths. COVIDENCE UK was set up with the specific purpose of investigating incident COVID-19, and consequently our questionnaires were specifically designed to capture contemporaneous and granular detail on potential risk factors, including behaviours influencing risk of exposure to SARS-CoV-2. Our finding that visits to other households and indoor public places were associated with increased risk of disease supports the case for restricting such activities as a public health strategy to control disease. Our low rates of loss to follow-up reflect the very high degree of participant engagement with the COVIDENCE UK Study. Our ability to identify episodes of milder disease affords potential insights into susceptibility factors as well as severity factors, and sets our study apart from long-established cohort studies in which assessment of risk factors may be temporally remote, and capture of outcomes is limited to events that are fatal or that precipitate hospitalisation. Our prospective design, coupled with censoring events occurring within 30 days of enrolment, minimises the potential for reverse causation to explain associations observed.

Our study also has limitations. Use of test-confirmed COVID-19 as our primary outcome may have resulted in underascertainment of disease, particularly early in the pandemic (when testing capacity was particularly limited) and among people with less access to testing services; this might introduce collider bias.\(^13\) We addressed this limitation by including a secondary outcome of symptom-defined probable COVID-19, which did not rely on access to testing. However, the lack of direct swabbing surveillance and reliance on results of routine testing that will usually have been prompted by incident symptoms may have led to underascertainment of asymptomatic SARS-CoV-2 infection. A second issue relates to the self-selected nature of the cohort participants. Ethnic minorities, particularly people of black, African and Caribbean ethnic origin, were under-represented in the study; a lack of statistical power may explain why we did not confirm an increased risk of disease in these groups. People with limited internet access or with fewer digital skills are also less likely to have participated. However, lack of representativeness in a study population does not preclude identification of causal associations.\(^24\) Third, as with any observational study, we cannot exclude the possibility that the associations we report may be explained by residual and/or unmeasured confounding. We sought to minimise this by capture of, and mutual adjustment for, a comprehensive panel of potential confounders. Calculation of E-values enabled us to determine how likely it was that our main findings might be ‘explained away’ by unmeasured/unknown confounding factors. For example, for an unknown confounder to fully explain the association between frequent visits to shops/indoor places and COVID-19 risk (OR 2.63 comparing top vs bottom quartile of exposure), it would need to be associated with both the outcome and the exposure (above and beyond the measured confounders) by an OR of nearly 5 or more (\textit{table 3}); weaker confounding could not explain away the association. In contrast, for the association between >9hours’ sleep and COVID-19 risk (OR 1.29) to be explained away, an unknown confounder would need to be associated with the exposure and outcome by an OR of at least 1.90; this effect estimate is comparable with other risk factor associations we have found, and hence is more plausible for an unknown confounder. Accordingly, evidence for an unconfounded, causal association is considerably stronger for frequent visits to shops/indoor places than it is for prolonged sleep duration.

In conclusion, this population-based longitudinal study conducted in UK adults found that increased risk of developing COVID-19 associated independently with Asian/Asian British ethnicity, household overcrowding, visits to other households and other indoor public places, frontline occupation outside of health or social care, and increased BMI, after rigorous adjustment for multiple confounders. Atopic diseases, and especially atopic asthma, were associated with decreased risk. In contrast to studies investigating risk factors for severe disease, older age, male sex and other comorbidities were not associated with increased risk of developing COVID-19.

\textbf{Author affiliations}

1Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
2Jane Symons Media, London, UK
3Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
4Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
5National Heart and Lung Institute, Imperial College London, London, UK
6Edenfield Road Surgery, Rochdale, UK
7Department of Radiology, Salisbury District Hospital, Salisbury, UK
8School of Dentistry, Institute of Clinical Sciences, University of Birmingham, Birmingham, UK
9Population Data Science, Swansea University Medical School, Swansea, UK

Holt H, et al. Thorax 2022;77:900–912. doi:10.1136/thoraxjnl-2021-217487

911

Thorax: first published as 10.1136/thoraxjnl-2021-217487 on 30 November 2021. Downloaded from http://thorax.bmj.com/ on September 8, 2022 by guest. Protected by copyright.
REFERENCES

1. Aburto JM, Kashyap R, Schöley J, et al. Estimating the burden of the COVID-19 pandemic on mortality, life expectancy and life span inequality in England and Wales: a population-level analysis. Epidemiol Community Health 2021;75:375–40.

2. Miller IF, Becker AD, Grenfell BT, et al. Disease and healthcare burden of COVID-19 in the United States. Nat Med 2020;26:1212–7.

3. Piñarré I, Arosas H, Acosta E, López-Casasnovas G, et al. Years of life lost to COVID-19 in 81 countries. Sci Rep 2021;11:3504.

4. Cift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 2020;371:m3731.

5. Williamson EM, Walker AI, Bhakara K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430–6.

6. Venkatesan P. The changing demographics of COVID-19. Lancet Respir Med 2020;8:e95.

7. Ward H, Atchison C, Whittaker M. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults. MedRxiv 2020.

8. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCOVPop): a population-based study. Lancet 2020;396:313–9.

9. Bhal A, Curry G, Martineau AR, et al. Sharpening the global focus on ethnicity and race in the time of COVID-19. Lancet 2020;395:1673–6.

10. Martineau AR, Fother SC. Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrinol 2020;8:735–6.

11. Hamer M, Kimikäi M, Galé CR, et al. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: a community-based cohort study of 387,109 adults in the United Kingdom. Brain Behav Immun 2020;87:184–7.

12. Menni C, Valdes AM, Freidin MB, et al. Real-Time tracking of self-reported symptoms to predict potential COVID-19. Nat Med 2020;26:1037–40.

13. Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun 2020;11:5749.

14. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43–6.

15. Ding P, VanderWeele TJ. Sensitivity analysis without assumptions. Epidemiology 2016;27:368–77.

16. Linden A, Mathur MB, VanderWeele TJ. Conducting sensitivity analysis for unmeasured confounding in observational studies using E-values: the evalvalue package. Stat J 2020;20:162–75.

17. Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 2020;146:203–6.

18. Mathur R, Rentchst C, The OpenSAFELY Collaborative. Ethnic differences in COVID-19 infection, hospitalisation, and mortality: an OpenSAFELY analysis of 17 million adults in England. MedRxiv 2020.

19. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev 2020;21:e13128.

20. Ho FK, Cellis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open 2020;10:e040002.

21. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of general practitioners research and surveillance centre primary care network: a cross-sectional study. Lancet Infect Dis 2020;20:1034–42.

22. Ma H, Zhou T, Heianza Y, et al. Habitual use of vitamin D supplements and risk of COVID-19 in 2019 (COVID-19) infection: a prospective study in UK Biobank. Am J Clin Nutr 2021;113:1275–81.

23. Louca P, Murray B, Klaser K, et al. Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 symptom study. APP: BMJ Nutr Prev Health 2021;4:149–57.

24. Doll R, Hill AB. Mortality in relation to smoking: ten years’ observations of British doctors. Br Med J 1966;1:1460–7.